Key facts
- This page summarizes Harrison Ross's Form 4 filing for MARIZYME INC (MRZM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Mar 2022, 07:48.
Harrison Ross - 17 Mar 2022 Form 4 Insider Report for MARIZYME INC (MRZM)
- Reporting relationship
- Vice President of Finance
- Issuer ticker
- MRZM
- Reported as of
- 17 Mar 2022
- Net transaction value
- +$24,638
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2022, 07:48:51 UTC
- Prior SEC filing
- 13 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harrison Ross
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Harrison Ross filed Form 4 for MARIZYME INC (MRZM) on 21 Mar 2022.
Change
- Previous filing in this sequence was filed on 13 Jan 2022.
- Current net transaction value: +$24,638.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRZM
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- $24,638
- Shares
- +273,750
- Change %
- Price
- $0.0900
- Shares after
- 273,750
- Date
- 17 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 273,750
- Exercise price
- $1.01
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The total purchase price of the stock option was $25,000.